| P50 | author | Cristina Diaz De Heredia | Q43175394 |
| | Carlos Palacio | Q83011236 |
| P2093 | author name string | José Sánchez de Toledo | |
| | Izaskun Elorza | |
| | Laura Gallur | |
| | Jose Luis Dapena | |
| P2860 | cites work | Detection of minimal residual disease in acute leukemia by flow cytometry | Q33707273 |
| | Detection of minimal residual disease (MRD) after bone marrow transplantation (BMT) by multi-parameter flow cytometry (MPFC). | Q33752925 |
| | Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. | Q35134983 |
| | Why and how to quantify minimal residual disease in acute lymphoblastic leukemia? | Q36736174 |
| | Status of minimal residual disease testing in childhood haematological malignancies | Q37246360 |
| | Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. | Q38455373 |
| | Is there a role for minimal residual disease levels in the treatment of ALL patients who receive allogeneic stem cells? | Q40432669 |
| | The immunologic detection of minimal residual disease in acute leukemia. | Q43575349 |
| | Long-term results of two consecutive trials in childhood acute lymphoblastic leukaemia performed by the Spanish Cooperative Group for Childhood Acute Lymphoblastic Leukemia Group (SHOP) from 1989 to 1998. | Q44456137 |
| | Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible. | Q44501485 |
| | Minimal residual disease detection after allogeneic stem cell transplantation is correlated to relapse in patients with acute lymphoblastic leukaemia | Q44505579 |
| | Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a prospective study | Q46529375 |
| | Four-color flow cytometry bypasses limitations of IG/TCR polymerase chain reaction for minimal residual disease detection in certain subsets of children with acute lymphoblastic leukemia | Q47299656 |
| | Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. | Q52914164 |
| | Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. | Q54114743 |
| | Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches. | Q54507169 |
| | Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia. | Q54614860 |
| | Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy? | Q54719477 |
| | Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR | Q60028872 |
| | Pediatric marrow transplantation for acute leukemia using unrelated donors and T-replete or -depleted grafts: a case-matched analysis | Q61851832 |
| | Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia | Q73052904 |
| | Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children | Q73283122 |
| | Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 TRIAL | Q74063860 |
| | Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia | Q74282286 |
| | Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia | Q74408930 |
| | The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia | Q74459338 |
| | Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group | Q79103069 |
| | Comparison of intensive chemotherapy, allogeneic, or autologous stem-cell transplantation as postremission treatment for children with very high risk acute lymphoblastic leukemia: PETHEMA ALL-93 Trial | Q79460529 |
| | Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping | Q80419584 |
| P433 | issue | 6 | |
| P921 | main subject | leukemia | Q29496 |
| | flow cytometry | Q1141429 |
| P304 | page(s) | 936-941 | |
| P577 | publication date | 2010-02-23 | |
| P1433 | published in | Haematologica | Q5638209 |
| P1476 | title | Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia | |
| P478 | volume | 95 | |